ALS News Today Home | ALS News Today
WEB4 days ago · RAG-17, an investigational therapy from Ractigen Therapeutics, was safe and well tolerated across all tested doses in people with amyotrophic lateral sclerosis (ALS) carrying mutations in the SOD1 gene — cases in which the disease is known as SOD1-ALS. Those are the findings of an investigator-initiated trial (NCT05903690)….
ALS News Today Forums
WEBNavigating ALS Challenges. This is a space for discussing daily life and challenges related to ALS. Diagnosis Information and General Questions Mobility Aides, Assistive Technology and Medical Equipment ALS and Relationships. 3 weeks, 6 days ago.
Different Stages of ALS Linked to Certain Blood Markers, Study …
WEBApr 1, 2019 · In the recruited group, there were 106 stage 1 patients, 240 stage 2 patients, 131 stage 3 patients, and 37 stage 4 patients. The investigators compared the levels of various molecules in the blood between ALS patients and controls and between patients at different stages of ALS. Most notably, the researchers found that uric acid (an ...
Amyotrophic Lateral Sclerosis (ALS) Treatment - ALS News Today
WEBApr 11, 2024 · Riluzole formulations. Riluzole was the first treatment to be approved for ALS by the FDA in 1995. The therapy is thought to work by reducing molecular signaling, which can overstimulate and damage nerve cells. The original formulation of riluzole is an oral tablet marketed under the brand name Rilutek by Covis Pharma.
Amyotrophic Lateral Sclerosis (ALS) Symptoms – ALS News Today
WEBFeb 6, 2023 · Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder in which worsening muscle weakness leads to movement problems and other symptoms such as trouble swallowing, speaking, and breathing. Patients also can experience digestive issues, mental health problems, and changes in behavior. Also known as …
News Archives - ALS News Today
WEBThe U.S. Food and Drug Administration (FDA) has given the green light to Dr.Noah Biotech to initiate a Phase 1 clinical trial of NDC-011, a combination therapy for amyotrophic lateral sclerosis (ALS), in healthy volunteers. The trial, planned for the first half of 2025 at a single site…. September 11, 2024 News by Andrea Lobo, PhD.
ALS Facts and Statistics – ALS News Today
WEBThe disease is most common among people 60 years or older, but nearly 10 percent of ALS patients are 45 or younger. Although ALS is 20 percent more likely to develop in men than in women, with advancing age, the gender difference disappears. Moreover, Caucasians and non-Hispanics are more likely to develop ALS compared with other ethnic groups.
What is Amyotrophic Lateral Sclerosis (ALS)? | ALS News Today
WEBMar 20, 2023 · FAQs. Amyotrophic lateral sclerosis (ALS) is a progressive neurological disorder that damages nerve cells and causes disability. The condition also is known as Lou Gehrig’s disease, after the famed New York Yankees baseball player who was diagnosed with the disorder in the late 1930s. ALS specifically damages motor neurons, the nerve cells ...
#AANAM – ALS Therapy AP-101 Safe, Well-tolerated in Phase 1 Trial
WEBApr 20, 2021 · In a Phase 1 trial for amyotrophic lateral sclerosis (ALS), the investigational therapy AP-101 — designed to ease motor symptoms and increase survival in people with the neurodegenerative disease — was found to be safe and well-tolerated at all tested doses.. The most commonly reported adverse events, or side effects, were related to the spinal tap during patient screening, according to ...
Clinical trial of oral ALS therapy SPG302 is enrolling in...
WEBby Andrea Lobo, PhD July 14, 2023. Spinogenix has launched a clinical trial in Australia to investigate its amyotrophic lateral sclerosis (ALS) treatment candidate SPG302 in patients and healthy volunteers. The first-in-human Phase 1 clinical trial (NCT05882695), which is recruiting up to 112 participants, is being conducted at the Nucleus ...